{
    "id": 706,
    "fullName": "MET R988C",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MET R988C (corresponds to R970C in the canonical isoform) lies within the juxtamembrane domain of the Met protein (PMID: 14559814, UniProt.org). R988C does not increase Met phosphorylation, but results in increased phosphorylation of cellular proteins, and increased proliferation and migration of cultured cells (PMID: 14559814, PMID: 20670955, PMID: 22973954, PMID: 31004003).",
            "references": [
                {
                    "id": 332,
                    "pubMedId": 14559814,
                    "title": "c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/14559814"
                },
                {
                    "id": 2198,
                    "pubMedId": 20670955,
                    "title": "MET receptor sequence variants R970C and T992I lack transforming capacity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20670955"
                },
                {
                    "id": 15528,
                    "pubMedId": 31004003,
                    "title": "A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31004003"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2053,
                    "pubMedId": 22973954,
                    "title": "Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22973954"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "R988C",
    "createDate": "06/06/2014",
    "updateDate": "07/06/2019",
    "referenceTranscriptCoordinates": {
        "id": 144886,
        "transcript": "NM_001127500",
        "gDna": "chr7:g.116771869C>T",
        "cDna": "c.2962C>T",
        "protein": "p.R988C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 559,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing MET R998C demonstrated sensitivity to Xalkori (crizotinib) in culture (PMID: 17483355).",
            "molecularProfile": {
                "id": 810,
                "profileName": "MET R988C"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 333,
                    "pubMedId": 17483355,
                    "title": "An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17483355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7766,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a GIST patient harboring KIT S476I and MET R988C demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for 6 months (PMID: 25363205).",
            "molecularProfile": {
                "id": 26035,
                "profileName": "KIT S476I MET R988C"
            },
            "therapy": {
                "id": 4517,
                "therapyName": "Bevacizumab + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6478,
                    "pubMedId": 25363205,
                    "title": "Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25363205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12893,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "n a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) gastric or gastroesophageal cancer patients identified MET R988C and amplification of MET in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).",
            "molecularProfile": {
                "id": 29000,
                "profileName": "ERBB2 over exp MET R988C MET amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 810,
            "profileName": "MET R988C",
            "profileTreatmentApproaches": [
                {
                    "id": 1516,
                    "name": "MET Inhibitor",
                    "profileName": "MET R988C"
                }
            ]
        },
        {
            "id": 26035,
            "profileName": "KIT S476I MET R988C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29000,
            "profileName": "ERBB2 over exp MET R988C MET amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144886,
            "transcript": "NM_001127500",
            "gDna": "chr7:g.116771869C>T",
            "cDna": "c.2962C>T",
            "protein": "p.R988C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}